Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Institute of Rheumatology, Università Cattolica del Sacro Cuore, Rome, Italy.
Sci Rep. 2019 Jul 18;9(1):10420. doi: 10.1038/s41598-019-46927-w.
Overweight/obesity influence disease burden and clinical outcome of Rheumatoid Arthritis (RA). The impact of overweight/obesity on synovial tissue (ST) inflammation is largely unknown. Here, we investigated the histological and transcriptional signature of ST obtained from RA in different disease phases (disease onset, failure to first-line conventional DMARDs and in sustained clinical and ultrasound remission) finding that overweight/obese DMARDs naive RA showed higher likelihood of follicular synovitis, higher IHC scores for sublining inflammatory cells (CD68, CD21 and CD20) and higher IL-1RA plasma levels than normal weight RA. Regardless to the synovitis pattern, overweight/obese DMARDs naive RA showed a worse clinical response to "Treat-to-target" (T2T) than normal weight RA at 6 and 12 months follow-up. Conversely, MTX-IR RA did not show significant differences in synovial inflammation based on BMI category. Overweight/obese RA in stable clinical and US remission showed higher degree of residual synovitis in terms of sublining CD68, CD20 cells and lining and sublining CD3 compared to normal weight RA. Finally, gene expression profile analysis revealed that ST of overweight/obese DMARDs naive RA is enriched by CCL3 and MyD88 compared to normal weight RA in sustained disease remission, the latter correlating with BMI and IHC scores for synovial CD68 cells. These findings suggest that indeed overweight/obese RA show higher degree of synovitis at disease onset and after remission achievement that influences the response rate to T2T and should be considered within the management of patients with RA.
超重/肥胖会影响类风湿关节炎(RA)的疾病负担和临床结果。超重/肥胖对滑膜组织(ST)炎症的影响在很大程度上尚不清楚。在这里,我们研究了处于不同疾病阶段(疾病发作、一线常规 DMARD 治疗失败和持续临床及超声缓解)的 RA 患者的滑膜组织的组织学和转录特征,结果发现,超重/肥胖且未经 DMARD 治疗的 RA 患者出现滤泡性滑膜炎的可能性更高,滑膜下炎症细胞(CD68、CD21 和 CD20)的免疫组化评分更高,IL-1RA 血浆水平也更高,高于体重正常的 RA 患者。无论滑膜炎模式如何,超重/肥胖且未经 DMARD 治疗的 RA 患者在 6 个月和 12 个月的随访中对“达标治疗”(T2T)的临床反应比体重正常的 RA 患者更差。相反,基于 BMI 类别,MTX-IR RA 患者的滑膜炎症没有显著差异。在稳定的临床和超声缓解的超重/肥胖 RA 患者中,与体重正常的 RA 患者相比,ST 中滑膜下 CD68、CD20 细胞以及衬里和滑膜下 CD3 的细胞残留炎症程度更高。最后,基因表达谱分析显示,与持续缓解疾病的体重正常 RA 患者相比,超重/肥胖且未经 DMARD 治疗的 RA 患者的滑膜组织中 CCL3 和 MyD88 的表达水平更高,后者与 BMI 和滑膜 CD68 细胞的免疫组化评分相关。这些发现表明,超重/肥胖的 RA 患者在疾病发作和缓解后确实存在更高程度的滑膜炎,这会影响 T2T 的反应率,因此应在 RA 患者的管理中加以考虑。